Suppr超能文献

分期错误不能解释结肠癌标本中淋巴结数量与生存之间的关系。

Staging error does not explain the relationship between the number of lymph nodes in a colon cancer specimen and survival.

机构信息

Department of Surgery, University of Vermont College of Medicine, Burlington, VT 05401, USA.

出版信息

Surgery. 2010 Mar;147(3):358-65. doi: 10.1016/j.surg.2009.10.003. Epub 2009 Dec 3.

Abstract

BACKGROUND

Survival in colon cancer is greater in those patients who have more lymph nodes identified at resection and may be due to stage migration, confounding by treatment, social, or clinical characteristics. Identifying factor(s) responsible for the effect may represent an opportunity to improve quality of care for patients with colon cancer by increasing node counts in specimens.

METHODS

Cox proportional hazards models were created to analyze survival of 11,399 patients with stage I-III colon cancer from the Surveillance, Epidemiology and End Results (SEER)-Medicare database. The primary predictor variable was the number of lymph nodes identified. The models allowed adjustment for patient factors, use of chemotherapy, surgical specialty, and the average number of nodes identified by surgeon and hospital pathologist.

RESULTS

The number of nodes identified was related to survival. Compared to those with less than 7 nodes, patients with 7 to 11 nodes had a 13% lesser risk of death (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.76-0.99; P = .037). Patients with more than 12 nodes had a 17% lesser risk (HR, 0.83; 95% CI, 0.73-0.95; P = .005). Adjusting for selected patient demographic characteristics, receipt of chemotherapy, surgical specialty, and the average number of nodes identified per specimen by the surgeon or hospital did not significantly alter the relationship between number of nodes and survival.

CONCLUSION

These findings argue against understaging or confounding as the explanation for the inferior survival observed in patients with fewer nodes identified. National initiatives to increase the number of nodes identified in colon cancer specimens may not improve substantially the cancer-specific outcomes.

摘要

背景

在接受切除术的结肠癌患者中,那些淋巴结检出数量更多的患者生存情况更好,这可能是由于分期转移、治疗、社会或临床特征混杂所致。确定导致这种影响的因素可能代表着一个机会,可以通过增加标本中的淋巴结计数来提高结肠癌患者的护理质量。

方法

利用监测、流行病学和最终结果(SEER)-医疗保险数据库中的 11399 例 I-III 期结肠癌患者数据,创建 Cox 比例风险模型来分析患者生存情况。主要预测变量为检出的淋巴结数量。该模型允许对患者因素、化疗使用情况、手术专业和外科医生及医院病理学家检出的平均淋巴结数量进行调整。

结果

检出的淋巴结数量与生存相关。与检出淋巴结数少于 7 枚的患者相比,检出淋巴结数为 7 至 11 枚的患者死亡风险降低 13%(风险比[HR],0.87;95%置信区间[CI],0.76-0.99;P =.037)。检出淋巴结数超过 12 枚的患者死亡风险降低 17%(HR,0.83;95%CI,0.73-0.95;P =.005)。在调整选定的患者人口统计学特征、化疗使用情况、手术专业和外科医生或医院每例标本检出的平均淋巴结数量后,淋巴结数量与生存之间的关系并未发生显著改变。

结论

这些发现表明,检出淋巴结数较少的患者生存情况较差并非分期过低或混杂因素所致。旨在增加结肠癌标本中淋巴结检出数量的国家倡议可能不会显著改善癌症特异性结局。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验